Systematic identification of antifungal drug targets by a metabolic network approach
Fungal infections pose an increasing threat for the immunocompromised. Limitations in antifungal therapy arise from non-specific symptoms of infection, poor diagnostics and comparatively few options for treatment. Currently established antifungal drugs interfere with the fungal cell wall or plasma membrane and are characterized by limited efficacy, severe side effects, or emerging pathogen resistance. Despite their promise to serve as highly specific antifungal targets, fungal metabolic pathways have been widely neglected. Because of the fact that Aspergillus, the causative agent of aspergillosis, apparently...
Subversive pro- and anti-inflammation trade-offs promote infection by Listeria monocytogenes
Prof. Trinad Chakraborty - Justus-Liebig University, Giessen (DE)
Prof. Pascale cossart - Institut Pasteur (FR)
Prof. Marc Lecuit - Institut Pasteur (FR)
Dr. Didier cabanes - Institute for Molecular and Cell Biology (IBMC) (PT)
Dr. Anat Herskovits - University of Tel Aviv (IL)